BamSEC and AlphaSense Join Forces
Learn More

Amicus Therapeutics Inc.

NASDAQ: FOLD    
Share price (12/26/24): $9.77    
Market cap (12/26/24): $2.919 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 4 pages Portions Herein Identified by [***] Have Been Excluded From This Exhibit Because the Excluded Information Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. First Amendment to the Supply and Manufacturing Services Agreement
12/34/56
EX-10.4
from 10-K 56 pages Portions Herein Identified by [***] Have Been Excluded From This Exhibit Because the Excluded Information Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Second Restated Agreement
12/34/56
EX-10.3
from 10-Q 13 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 28 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 32 pages Portions Herein Identified by [***] Have Been Excluded From This Exhibit Because the Excluded Information Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Supply and Manufacturing Services Agreement Between Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, Pa 19104 and Wuxi Biologics (Hong Kong) Limited Flat/Rm826, 8/F Ocean Centre Harbour City, 5 Canton Road Tst, Hong Kong Wuxi Biologics Ireland Limited Mullagharlin, Dundalk, Co Louth A91 X56f, Ireland and Wuxi Biologics Germany Gmbh Chempark Leverkusen Building D 201, Tor 133 51368 Leverkusen Germany Confidential
12/34/56
EX-10.1
from 8-K 137 pages Material contract
12/34/56
EX-10.26
from 10-K 20 pages Portions Herein Identified by [***] Have Been Excluded From This Exhibit Because the Excluded Information Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Mutual Termination Agreement
12/34/56
EX-10.25
from 10-K 60 pages Portions Herein Identified by [***] Have Been Excluded From This Exhibit Because the Excluded Information Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. License Agreement Dated as of December 22, 2022 by and Between the Trustees of the University of Pennsylvania and Amicus Therapeutics, Inc
12/34/56
EX-10.19
from 10-K 15 pages Employment Agreement
12/34/56
EX-10.18
from 10-K 15 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 22 pages Indemnity Agreement
12/34/56
EX-10.1
from 8-K 15 pages Employment Agreement
12/34/56
EX-10.30
from 10-K 3 pages Seventh Amendment to Amended and Restated Research, Collaboration and License Agreement
12/34/56
EX-10.29
from 10-K 5 pages Portions Herein Identified by [***] Have Been Excluded From This Exhibit Because the Excluded Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Sixth Amendment to Amended and Restated Research, Collaboration and License Agreement
12/34/56
EX-10.28
from 10-K 6 pages Fifth Amendment to Amended and Restated Research, Collaboration and License Agreement
12/34/56
EX-10.27
from 10-K 6 pages Fourth Amendment to Amended and Restated Research, Collaboration and License Agreement
12/34/56
EX-10.2
from 8-K 14 pages Employment Agreement
12/34/56
EX-10.26
from 10-K 9 pages Third Amendment to Amended and Restated Research, Collaboration and License Agreement
12/34/56
EX-10.1
from 8-K 3 pages Termination Agreement
12/34/56
EX-10.25
from 10-K 3 pages Restricted Stock Unit Award Agreement
12/34/56